261 related articles for article (PubMed ID: 32657189)
1. Use of real-world evidence in meta-analyses and cost-effectiveness models.
Bowrin K; Briere JB; Levy P; Toumi M; Millier A
J Med Econ; 2020 Oct; 23(10):1053-1060. PubMed ID: 32657189
[TBL] [Abstract][Full Text] [Related]
2. Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.
Briere JB; Wu O; Bowrin K; Millier A; Toumi M; Taieb V; Levy P; Coleman CI
Curr Med Res Opin; 2019 Nov; 35(11):1867-1872. PubMed ID: 31328580
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness analyses using real-world data: an overview of the literature.
Bowrin K; Briere JB; Levy P; Millier A; Clay E; Toumi M
J Med Econ; 2019 Jun; 22(6):545-553. PubMed ID: 30816067
[No Abstract] [Full Text] [Related]
4. Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France.
Bowrin K; Briere JB; Fauchier L; Coleman C; Millier A; Toumi M; Clay E; Levy P
PLoS One; 2020; 15(1):e0225301. PubMed ID: 31978044
[TBL] [Abstract][Full Text] [Related]
5. The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France.
de Pouvourville G; Blin P; Karam P
Eur J Health Econ; 2020 Mar; 21(2):235-249. PubMed ID: 31650440
[TBL] [Abstract][Full Text] [Related]
6. Meta-analyses using real-world data to generate clinical and epidemiological evidence: a systematic literature review of existing recommendations.
Briere JB; Bowrin K; Taieb V; Millier A; Toumi M; Coleman C
Curr Med Res Opin; 2018 Dec; 34(12):2125-2130. PubMed ID: 30217138
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
8. Use of real-world evidence in economic assessments of pharmaceuticals in the United States.
Lee W; Dayer V; Jiao B; Carlson JJ; Devine B; Veenstra DL
J Manag Care Spec Pharm; 2021 Jan; 27(1):5-14. PubMed ID: 33377439
[No Abstract] [Full Text] [Related]
9. Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention.
Camm AJ; Fox KAA; Peterson E
Europace; 2018 Jan; 20(1):1-11. PubMed ID: 29040518
[TBL] [Abstract][Full Text] [Related]
10. Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review.
Briere JB; Bowrin K; Coleman C; Fauchier L; Levy P; Folkerts K; Toumi M; Taieb V; Millier A; Wu O
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):27-36. PubMed ID: 30169975
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
12. Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation.
Limone BL; Baker WL; Mearns ES; White CM; Kluger J; Coleman CI
J Clin Epidemiol; 2014 Oct; 67(10):1093-102. PubMed ID: 25018102
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China.
Dong SJ; Wu B; Zhai SD; Zhang YJ; Chu YB; Gupta P; Li YH
Clin Ther; 2020 Jan; 42(1):144-156.e1. PubMed ID: 31932080
[TBL] [Abstract][Full Text] [Related]
14. What Influences the Cost Effectiveness of Dabigatran versus Warfarin for Stroke Prevention in Atrial Fibrillation: A Systematic Review.
Jegathisawaran J; Holbrook A; Bowen JM; Burke N; Campbell K; Tarride JE
J Popul Ther Clin Pharmacol; 2017 May; 24(2):e1-e20. PubMed ID: 28594478
[TBL] [Abstract][Full Text] [Related]
15. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
[TBL] [Abstract][Full Text] [Related]
16. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
[No Abstract] [Full Text] [Related]
17. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
[TBL] [Abstract][Full Text] [Related]
18. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
López-López JA; Sterne JAC; Thom HHZ; Higgins JPT; Hingorani AD; Okoli GN; Davies PA; Bodalia PN; Bryden PA; Welton NJ; Hollingworth W; Caldwell DM; Savović J; Dias S; Salisbury C; Eaton D; Stephens-Boal A; Sofat R
BMJ; 2017 Nov; 359():j5058. PubMed ID: 29183961
[No Abstract] [Full Text] [Related]
19. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review.
Liberato NL; Marchetti M
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):221-35. PubMed ID: 26817497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
